Ocular Therapeutix, Inc.
- Jurisdiction
United States - LEI
529900ABAWFXOHSIHG03 - ISIN
US67576A1007 (OCUL )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
2
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
5
/ 7
Profile
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. Read full profile
Fundamentals
- Net revenue
€48.28M - Gross margin
89.4% - EBIT
-€194.59M - EBIT margin
-403.1% - Net income
-€184.88M - Net margin
-382.9%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
| Name | Title | Transaction Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Notman Donald | See Remarks |
|
|
|
|
| Dugel Pravin | See Remarks |
|
|
|
|
| Heier Jeffrey S. | Chief Scientific Officer |
|
|
|
|
| Kaiser Peter | Chief Development Officer |
|
|
|
|
| Nayak Sanjay | Chief Strategy Officer |
|
|
|
|
Earnings Calls
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Peter Brown |
|
|
|
Buy |
Earnings Calls
Latest earnings call: November 7, 2023 (Q3 2023)